1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow NUC-1031 750mg: new trials by email Literature Review of NUC-1031 750mg trials Research Report on NUC-1031 750mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer NUC-1031 500 mg, NUC-1031 750mg - Ovarian Cancer | Phase 2 | Terminated | NuCana plc | 53 | 2017-09-28 | 2021-02-21 |
Ovarian Diseases (1) · Ovarian Neoplasms (1)
NuCana plc (1)
United Kingdom (1) · United States (1)
2016 (1)